Product Image

Contributor Information

  • Name Julian Gannon
  • Institute Cancer Research UK, London Research Institute: Clare Hall Laboratories

Tool Details

  • Tool name: Anti-Cdk2 [AN4.3]
  • Alternate names: Cyclin-Dependent Kinase 2; Cell Division Protein Kinase 2; P33 Protein Kinase; CDKN2; CDC2-Related Protein Kinase; P33(CDK2)
  • Clone: AN4.3
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human ; Mouse ; Xenopus laevis
  • Host: Mouse
  • Application: ELISA ; FACS ; IP ; WB
  • Description: Cdk2 is a cell cycle protein closely related to Cdk1 (Cdc2) and a useful marker of proliferation. Cdk2 binds cyclins A and E and controls progression into S-phase.
  • Immunogen: Human recombinant Cdk2
  • Isotype: IgG2a
  • Research area: Cancer; Cell biology; Genetics
  • Myeloma used: Sp2/0-Ag14

  • For Research Use Only

Target Details

  • Target: Cyclin-dependent kinase 2 (cdk2)
  • Target background: Cdk2 is a cell cycle protein closely related to Cdk1 (Cdc2) and a useful marker of proliferation. Cdk2 binds cyclins A and E and controls progression into S-phase.

Application Details

  • Application: ELISA ; FACS ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

References

  •   Syafrizayanti et al. 2017. Sci Rep. 7:39756. PMID: 28045055.
  •   Personalised proteome analysis by means of protein microarrays made from individual patient samples.
  •   Chang et al. 2016. J Formos Med Assoc. :. PMID: 27773559.
  •   Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.
  •   Chu et al. 2016. Journal of Fn Foods. 23:614-627
  •   Xu et al. 2010. Biol Pharm Bull. 33(5):743-51. PMID: 20460749.
  •   Targeting the Na(+)/K(+)-ATPase alpha1 subunit of hepatoma HepG2 cell line to induce apoptosis and cell cycle arresting.
  •   Ottewell et al. 2009. Mol Cancer Ther. 8(10):2821-32. PMID: 19789217.
  •   Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.